ATE446092T1 - Verwendung von oxycodon zur behandlung von viszeralem schmerz - Google Patents

Verwendung von oxycodon zur behandlung von viszeralem schmerz

Info

Publication number
ATE446092T1
ATE446092T1 AT06700652T AT06700652T ATE446092T1 AT E446092 T1 ATE446092 T1 AT E446092T1 AT 06700652 T AT06700652 T AT 06700652T AT 06700652 T AT06700652 T AT 06700652T AT E446092 T1 ATE446092 T1 AT E446092T1
Authority
AT
Austria
Prior art keywords
oxycodone
visceral pain
treat visceral
treat
pain
Prior art date
Application number
AT06700652T
Other languages
English (en)
Inventor
Asbjorn Mohr Drewes
Lars Arendt Nielsen
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35871217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE446092(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of ATE446092T1 publication Critical patent/ATE446092T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
AT06700652T 2005-01-18 2006-01-17 Verwendung von oxycodon zur behandlung von viszeralem schmerz ATE446092T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64549005P 2005-01-18 2005-01-18
PCT/EP2006/050252 WO2006077212A1 (en) 2005-01-18 2006-01-17 Use of oxycodone for treating visceral pain

Publications (1)

Publication Number Publication Date
ATE446092T1 true ATE446092T1 (de) 2009-11-15

Family

ID=35871217

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06700652T ATE446092T1 (de) 2005-01-18 2006-01-17 Verwendung von oxycodon zur behandlung von viszeralem schmerz
AT0014807U AT9895U1 (de) 2005-01-18 2007-03-09 Verfahren zur behandlung von viszeralem schmerz

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT0014807U AT9895U1 (de) 2005-01-18 2007-03-09 Verfahren zur behandlung von viszeralem schmerz

Country Status (32)

Country Link
US (2) US20080200493A1 (de)
EP (1) EP1838318B1 (de)
JP (1) JP5049139B2 (de)
KR (10) KR20080106991A (de)
CN (1) CN101106996B (de)
AP (1) AP2249A (de)
AR (1) AR052880A1 (de)
AT (2) ATE446092T1 (de)
AU (1) AU2006207498B2 (de)
BR (1) BRPI0606247A2 (de)
CA (1) CA2595043C (de)
CY (1) CY1109660T1 (de)
DE (2) DE602006009899D1 (de)
DK (2) DK1838318T3 (de)
EA (1) EA013544B1 (de)
ES (1) ES2333901T3 (de)
HK (1) HK1107933A1 (de)
HR (1) HRP20090679T1 (de)
IL (1) IL184530A (de)
ME (1) ME01066B (de)
MX (1) MX2007007207A (de)
MY (1) MY144471A (de)
NO (1) NO338968B1 (de)
NZ (1) NZ555852A (de)
PL (1) PL1838318T3 (de)
PT (1) PT1838318E (de)
RS (1) RS51069B (de)
SI (1) SI1838318T1 (de)
TW (1) TWI432196B (de)
UA (1) UA85471C2 (de)
WO (1) WO2006077212A1 (de)
ZA (1) ZA200705231B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2380592T3 (en) 2005-11-14 2018-03-19 Teva Pharmaceuticals Int Gmbh Antagonist antibody directed to calcitonin gene related peptide
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
CN107296957A (zh) 2008-03-04 2017-10-27 梯瓦制药国际有限责任公司 治疗慢性疼痛的方法
EP2393484A1 (de) 2009-02-06 2011-12-14 Egalet Ltd. Gegen missbrauch durch alkoholeinnahme widerstandsfähige zusammensetzung mit unmittelbarer freisetzung
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
KR101519192B1 (ko) * 2009-08-28 2015-05-11 리나트 뉴로사이언스 코프. 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
EP2709663B1 (de) 2011-05-20 2019-03-20 AlderBio Holdings LLC Verwendung von anti-cgrp-antikörpern und -antikörperfragmenten zur vorbeugung oder hemmung von photophobie oder lichtabneigung bei darauf angewiesenen personen, insbesondere migränepatienten
EA039905B1 (ru) 2011-05-20 2022-03-25 Х. Лундбек А/С Анти-cgrp антитела и их применение
BR112013029951B1 (pt) 2011-05-20 2020-10-20 Alderbio Holdings Llc composição farmacêutica e uso de anticorpos ou fragmentos de anticorpos anti-cgrp para tratar ou prevenir formas de diarreia crônicas e agudas
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
CA2943551A1 (en) 2014-03-21 2015-09-24 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
BR112019005823A2 (pt) 2016-09-23 2019-06-25 Teva Pharmaceuticals Int Gmbh tratamento para enxaqueca refratária
US11400052B2 (en) 2018-11-19 2022-08-02 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
EP3908606A4 (de) 2019-01-08 2022-11-23 H. Lundbeck A/S Akute behandlung und schnelle behandlung von kopfschmerzen mit anti-cgrp-antikörpern

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
EA000976B1 (ru) * 1996-03-25 2000-08-28 Эли Лилли Энд Компани Композиция для снятия боли и способ снятия боли
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US6992193B2 (en) * 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use

Also Published As

Publication number Publication date
NO338968B1 (no) 2016-11-07
WO2006077212A1 (en) 2006-07-27
DK200700207U3 (da) 2007-09-28
HK1107933A1 (en) 2008-04-25
KR20230170811A (ko) 2023-12-19
KR20120089710A (ko) 2012-08-13
US9271974B2 (en) 2016-03-01
CN101106996B (zh) 2013-10-23
AP2249A (en) 2011-07-18
SI1838318T1 (sl) 2010-02-26
EP1838318B1 (de) 2009-10-21
MY144471A (en) 2011-09-30
KR20070100368A (ko) 2007-10-10
IL184530A (en) 2015-01-29
JP5049139B2 (ja) 2012-10-17
CA2595043A1 (en) 2006-07-27
IL184530A0 (en) 2007-10-31
TW200637554A (en) 2006-11-01
NO20074174L (no) 2007-10-17
EA200701541A1 (ru) 2008-02-28
US20150190393A1 (en) 2015-07-09
US20080200493A1 (en) 2008-08-21
DK1838318T3 (da) 2010-01-04
UA85471C2 (ru) 2009-01-26
AP2007004057A0 (en) 2007-08-31
DK200700207U1 (da) 2007-08-24
EA013544B1 (ru) 2010-06-30
HRP20090679T1 (hr) 2010-01-31
EP1838318A1 (de) 2007-10-03
AU2006207498A1 (en) 2006-07-27
NZ555852A (en) 2010-01-29
BRPI0606247A2 (pt) 2009-06-09
RS51069B (sr) 2010-10-31
ES2333901T3 (es) 2010-03-02
DE602006009899D1 (de) 2009-12-03
CA2595043C (en) 2013-11-19
PL1838318T3 (pl) 2010-03-31
AT9895U1 (de) 2008-05-15
TWI432196B (zh) 2014-04-01
KR20210131450A (ko) 2021-11-02
CN101106996A (zh) 2008-01-16
JP2008526927A (ja) 2008-07-24
AR052880A1 (es) 2007-04-11
KR20080106991A (ko) 2008-12-09
CY1109660T1 (el) 2014-08-13
KR20220165797A (ko) 2022-12-15
ME01066B (me) 2012-10-20
PT1838318E (pt) 2009-12-15
KR20140091782A (ko) 2014-07-22
DE202006019887U1 (de) 2007-07-26
KR20190135557A (ko) 2019-12-06
KR20200128451A (ko) 2020-11-12
KR20170021905A (ko) 2017-02-28
MX2007007207A (es) 2007-08-15
ZA200705231B (en) 2008-06-25
AU2006207498B2 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
ATE446092T1 (de) Verwendung von oxycodon zur behandlung von viszeralem schmerz
ATE534379T1 (de) Neue verwendung von peptid-verbindungen zur behandlung von muskelschmerzen
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
ATE521352T1 (de) Verwendung von flibanserin zur behandlung von prämenopausalen störungen der sexuellen lust
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
EP1838714A4 (de) Verfahren zur behandlung von schmerzen
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
ATE483460T1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
DE502005003840D1 (de) Anlage zur nichtinvasiven medizinischen behandlung
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602006021192D1 (de) Visnadin zur Behandlung von Kopfhautjucken
DE602007009877D1 (de) Isosorbid-mononitrat-derivate zur behandlung von darmerkrankungen
ZA200703531B (en) Use of androgens to reduce the likelihood of acquiring or to treat skin aging
ATE504307T1 (de) Verwendung von gallium (iii) komplexen zur behandlung von melanomen
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
DE602005015442D1 (de) Kollagen-polyvinylpyrrolidon zur behandlung von osteoarthritis
ATE534392T1 (de) Verwendung eines neuen therapeutikums zur behandlung von leukämie
ATE537123T1 (de) Verfahren zur biologischen aufbereitung von badewasser
DE502005002104D1 (de) Hesperidin zur Behandlung von Epilepsie
DE602007003350D1 (de) Behandlung von polysilazan-abfall
ATE521351T1 (de) Verwendung von 7-t-butoxyiminomethylcamptothecin zur behandlung von gebärmuttertumoren
ATE345134T1 (de) Verwendung von indazol-derivaten zur behandlung von neuropathischen schmerzen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1838318

Country of ref document: EP